Allurion Technologies (ALURW) Cash from Financing Activities (2022 - 2026)
Allurion Technologies (ALURW) reported Cash from Financing Activities of $2.9 million for Q1 2026, down 80.23% on a YoY basis from $14.5 million in Q1 2025, and down 37.65% quarter-over-quarter from $4.6 million in Q4 2025.
Allurion Technologies (ALURW) Cash from Financing Activities (2022 - 2026) Analysis & Trends
Allurion Technologies has reported Cash from Financing Activities for 5 years, with the latest figure at $2.9 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities fell 80.23% year-over-year to $2.9 million; the trailing twelve-month figure through Mar 2026 stood at $7.3 million (down 78.62% YoY), and the FY2025 full-year result was $19.0 million, down 6.13% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $2.9 million, down from $4.6 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $98.9 million in Q3 2023, with the low at -$20.4 million in Q4 2023.
- Historically, Cash from Financing Activities has averaged $10.8 million across 5 years, with a median of $4.6 million in 2025.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities tumbled 239.4% — and 2025, when it surged 8773.58%.
- Allurion Technologies' Cash from Financing Activities stood at $14.6 million in 2022, then plunged by 239.4% to -$20.4 million in 2023, then jumped by 99.74% to -$53000.0 in 2024, then surged by 8773.58% to $4.6 million in 2025, then slumped by 37.65% to $2.9 million in 2026.
- The last three Cash from Financing Activities figures came in at $2.9 million (Q1 2026), $4.6 million (Q4 2025), and -$55000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | -2.09 Bn |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | -26.93 Mn |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | -25.00 Mn |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 21.00 Mn |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | -97.90 Mn |
| 10 | Allurion Technologies | - | - | 1.23 Mn | 2.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.87 Mn |
| Mar 31, 2026 | 2.87 Mn |
| Dec 31, 2025 | 4.60 Mn |
| Dec 31, 2025 | 4.60 Mn |
| Sep 30, 2025 | -55,000.00 |
| Sep 30, 2025 | -55,000.00 |
| Jun 30, 2025 | -71,000.00 |
| Jun 30, 2025 | -71,000.00 |
| Mar 31, 2025 | 14.50 Mn |
| Mar 31, 2025 | 14.50 Mn |
| Dec 31, 2024 | -53,000.00 |
| Dec 31, 2024 | -53,000.00 |
| Sep 30, 2024 | 20.93 Mn |
| Sep 30, 2024 | 20.93 Mn |
| Jun 30, 2024 | -1.06 Mn |
| Jun 30, 2024 | -1.06 Mn |
| Mar 31, 2024 | 387,000.00 |
| Mar 31, 2024 | 387,000.00 |
| Dec 31, 2023 | -20.41 Mn |
| Dec 31, 2023 | -20.41 Mn |